Patent · US Active

Anti-EGFR antibody-drug conjugates

US11759527B2 · kind B2 · utility

0Cited by

189References

3Claims

0Family size

Assignee

Abb Vie Inc. · US

Inventors

Erwin R. Boghaert · Pleasant Prairie, US
Andrew C. Phillips · Libertyville, US
Andrew J. Souers · Libertyville, US
Kamel Izeradjene · Gurnee, US
John E. Harlan · Lake Zurich, US

Key dates

Filing date	Jan 20, 2022
Grant date	Sep 19, 2023
Priority date	—
Expiry date	May 2, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.